CBLI Stock Forecast and Price Target (Cleveland BioLabs stock)

CBLI Stock Trend

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled.

Given the current short-term trend, the stock is expected to fall -36.22% during the next 3 months and, with a 90% probability hold a price between $1.18 and $2.60 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

WARNING: Trend forecast is still in the development phase and should be used with caution. Some cases might produce unexpected results such as negative prices at the end of the trend.

Data

Date	Bottom	Mid	Top
2021-09-22	$1.82	$2.93	$4.05
2021-09-23	$1.78	$2.90	$4.01
2021-09-24	$1.75	$2.86	$3.97
2021-09-27	$1.71	$2.82	$3.94
2021-09-28	$1.67	$2.79	$3.90
2021-09-29	$1.64	$2.75	$3.86
2021-09-30	$1.60	$2.71	$3.82
2021-10-01	$1.56	$2.68	$3.79
2021-10-04	$1.53	$2.64	$3.75
2021-10-05	$1.49	$2.60	$3.71
2021-10-06	$1.45	$2.56	$3.68
2021-10-07	$1.42	$2.53	$3.64
2021-10-08	$1.38	$2.49	$3.60
2021-10-11	$1.34	$2.45	$3.57
2021-10-12	$1.31	$2.42	$3.53
2021-10-13	$1.27	$2.38	$3.49
2021-10-14	$1.23	$2.34	$3.46
2021-10-15	$1.19	$2.31	$3.42
2021-10-18	$1.16	$2.27	$3.38
2021-10-19	$1.12	$2.23	$3.35
2021-10-20	$1.08	$2.20	$3.31
2021-10-21	$1.05	$2.16	$3.27
2021-10-22	$1.01	$2.12	$3.24
2021-10-25	$0.97	$2.09	$3.20
2021-10-26	$0.94	$2.05	$3.16
2021-10-27	$0.90	$2.01	$3.13
2021-10-28	$0.86	$1.98	$3.09
2021-10-29	$0.83	$1.94	$3.05
2021-11-01	$0.79	$1.90	$3.02
2021-11-02	$0.75	$1.87	$2.98

About Cleveland BioLabs

Cleveland BioLabs, Inc., a biopharmaceutical company, focuses on developing pharmaceuticals designed to address diseases with unmet medical need. Its lead drug candidate includes Entolimod, a Toll-like receptor 5 (TLR5) agonist, which is used for the prevention of death from acute radiation syndrome, and is used as an oncology drug. The company is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics n... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!